NYU Langone Insights on Psychiatry

The Neurology and Psychiatry of Complex Brain Injury Care Feb 02, 2026

Lindsey Gurin, MD, discusses how clinicians can approach patients whose symptoms fall at the intersection of psychiatry and neurology. Drawing on her work with traumatic brain injury, PTSD, and persistent post-concussive symptoms, she explains why attempts to separate psychological trauma from neurological injury often obscure what patients actually need.

The conversation explores identity disruption after brain injury, the unintended effects of rigid recovery timelines, and the importance of continuity in understanding symptoms over time. Dr. Gurin also discusses how neurodevelopmental traits such as ADHD shape vulnerability and treatment response, when stimulant medications can be appropriate after concussion, and why breaking complex presentations into treatable components often matters more than assigning a single diagnosis.

Lindsey Gurin, MD, is Assistant Professor in the Departments of Neurology, Psychiatry, and Rehabilitation Medicine at NYU Langone Health, and Director of the Neurology/Psychiatry Residency Program.

▶️ Watch Insights on Psychiatry on YouTube

00:00 Brain Injury and Identity
01:27 What Is the Psychiatry–Neurology Double Board?
02:41 Why PTSD and TBI Overlap
03:28 What “Shell Shock” Really Means
06:00 When Concussion Symptoms Don’t Go Away
07:25 Life Before vs After Brain Injury
08:46 ADHD as a Hidden Risk Factor
10:28 Using Stimulants After Brain Injury
12:40 Rethinking “Post-Concussion Syndrome”
13:27 The Future of Neuropsychiatric Care

This episode is intended for psychiatrists and other clinicians caring for patients with complex neuropsychiatric presentations at the intersection of psychiatry and neurology.

This discussion is for educational purposes and does not substitute for individual clinical judgment or patient care.

Senior Producer: Jon Earle

Psychedelics for Treatment-Resistant Disorders Jan 26, 2026

Michael Bogenschutz, MD, explains how psychedelic-assisted treatments may offer new options for patients with severe, treatment-refractory psychiatric conditions. He discusses why standard approaches often fall short for complex cases, how psychedelics like psilocybin and MDMA differ from conventional medications, and what careful screening and clinical structure make these treatments safe and effective.

Drawing on randomized clinical trials and years of clinical experience, Dr. Bogenschutz describes how psychedelic treatments can produce durable symptom improvement in disorders such as alcohol use disorder and trauma-related conditions. He also explores unresolved scientific questions, including whether the psychedelic experience itself is necessary for therapeutic benefit.

Michael Bogenschutz, MD, is Professor of Psychiatry and Director of the Center for Psychedelic Medicine at NYU Langone Health.

▶️ Watch Insights on Psychiatry on YouTube

00:00 A Remarkable Case: Sustained Sobriety After Psilocybin Treatment
00:39 Introducing Dr. Michael Bogenschutz
01:04 Why Psychiatry Is Re-Examining Psychedelics
02:50 Safety, Screening, and Managing the Psychedelic Experience
03:45 Landmark Trial: Psilocybin for Alcohol Use Disorder
06:16 How Psychedelics Work: Neuroplasticity vs. Subjective Experience
08:53 Can Non-Psychedelic Analogs Deliver the Same Benefits?
11:47 MDMA, Fear Reduction, and Emotional Processing
13:44 Who Benefits Most? A Composite of Treatment-Refractory Patients
15:45 The Future of Psychedelic Psychiatry at NYU

This episode is intended for psychiatrists, mental health clinicians, and others interested in complex and treatment-resistant psychiatric conditions.

This discussion is for educational purposes and does not substitute for individual clinical judgment or patient care.

Senior Producer: Jon Earle

Treating ADHD in Patients With Bipolar Disorder and Substance Use Jan 19, 2026

Lenard Adler, MD, explains how clinicians can safely and effectively treat ADHD when bipolar disorder and addiction are also in the picture. He addresses how to distinguish chronic ADHD symptoms from episodic mood disorders, why bipolar disorder is often missed in adults referred for depression or attention problems, and how substance use complicates both diagnosis and medication selection.

Dr. Adler also shares guidance on identifying red flags for diversion or misuse, setting appropriate expectations for medication trials, and navigating the limits of current treatment guidelines. The episode closes with a look toward emerging directions in ADHD treatment, including research on emotional dysregulation, executive function deficits, and next-generation neurofeedback approaches.

Lenard Adler, MD, is Pottash Professor of Psychiatry and Director of the Adult ADHD Program at NYU Langone Health

▶️ Watch Insights on Psychiatry on YouTube

00:00 Why ADHD, Bipolar Disorder, and Addiction Must Be Treated Together
01:02 What Makes These ADHD Cases So Difficult
02:05 ADHD vs. Bipolar Disorder: Key Diagnostic Distinctions
04:43 The Link Between ADHD and Addiction
05:53 Using Stimulants Safely When Substance Use Is a Concern
07:57 Choosing Stimulants vs. Non-Stimulants
10:07 How Severity and Comorbidity Shape Treatment Decisions
12:06 The Limits of Guidelines and Biomarkers in ADHD Care
15:34 Executive Function and Emotional Dysregulation
16:13 Where ADHD Treatment Is Headed Next

This episode is intended for psychiatrists, mental health clinicians, and others interested in complex adult ADHD presentations.

This discussion is for educational purposes and does not substitute for individual clinical judgment or patient care.

Senior Producer: Jon Earle

Delivering Addiction Care Outside Traditional Settings Jan 12, 2026

Ayana Jordan, MD, PhD, discusses how precision psychiatry must expand beyond biology to address the social, cultural, and structural realities shaping addiction and mental health care for historically underrepresented patients. The conversation explores how trauma, poverty, housing instability, health literacy, and stigma interact with substance use and serious mental illness—and why traditional clinic-based models often fail to meet patients where they are.

Dr. Jordan describes the work of the Jordan Wellness Collaborative, including partnerships that integrate addiction treatment into primary care, community settings, and faith-based institutions. She explains how peer facilitators, housing support, and trusted community spaces can dramatically improve engagement, retention, and outcomes. Looking ahead, she reflects on how emerging tools—from AI-supported care models to novel treatments for addiction—may further transform access and equity in psychiatric care.

Ayana Jordan, MD, PhD, is the Barbara Wilson Professor of Psychiatry at NYU Grossman School of Medicine and Principal Investigator of the Jordan Wellness Collaborative.

▶️ Watch Insights on Psychiatry on YouTube

TOPICS

Expanding precision psychiatry beyond biological models
Structural barriers to care: housing, literacy, and stigma
Addiction treatment for historically underrepresented communities
Integrating care into primary care, community, and faith-based settings
The role of peer facilitators and lived experience in treatment
Trust, safety, and engagement for patients with complex needs
Future directions: AI, novel addiction treatments, and workforce training

This discussion is for educational purposes and does not substitute for individual clinical judgment or patient care.

Senior Producer: Jon Earle

Bipolar Depression and Mixed Episodes: Rethinking Treatment Goals Jan 02, 2026

Dan Iosifescu, MD, discusses why bipolar depression and mixed episodes remain among the most difficult—and highest-risk—conditions in psychiatry. Even when mood symptoms improve, many patients continue to experience significant cognitive and functional impairment. Dr. Iosifescu argues that standard approaches often fall short because symptom suppression is mistaken for recovery, short-term improvement is confused with durable treatment, and mixed episodes expose the limits of one-size-fits-all care.

The conversation explores the clinical dangers of mixed episodes, the challenge of recognizing them, and the importance of moving deliberately from acute stabilization to sustainable long-term treatment.

Dan Iosifescu, MD, is Director of Clinical Research at the Nathan Kline Institute and Director of the Mood Disorders Clinical and Research Program at NYU Langone Health.

▶️ Watch Insights on Psychiatry on YouTube

00:33 Introduction
01:22 Challenges of Treating Bipolar Depression
02:58 Case Study: The Impact of Bipolar Depression
05:01 Novel Treatments and Approaches
07:23 Understanding and Managing Mixed Episodes
13:44 Future Directions in Bipolar Disorder Treatment
16:09 Innovative Research at NYU Psychiatry
22:33 Conclusion and Final Thoughts

This episode is intended for psychiatrists, mental health clinicians, and others interested in treatment-resistant forms of depression and bipolar disorder.

This discussion is for educational purposes and does not substitute for individual clinical judgment or patient care.

Senior Producer: Jon Earle

Interventional Approaches to Treatment-Resistant Mood Disorders Dec 26, 2025

Joshua Berman, MD, PhD, discusses how careful evaluation, patient priorities, and risk-benefit tradeoffs guide the use of interventional treatments when conventional approaches fall short. Dr. Berman also explains how tools such as ketamine, TMS, ECT, and neurofeedback can be used strategically—sometimes in sequence or combination—to address different vulnerabilities within mood-related brain circuits.

Dr. Berman is Associate Professor of Psychiatry and Director of Interventional Psychiatry at NYU Langone Health.

▶️ Watch Insights on Psychiatry on YouTube

00:47 What Is Interventional Psychiatry?
02:33 Evaluating Treatment-Resistant Presentations
06:31 Precision, Patient Priorities, and Clinical Judgment
09:35 Sequencing and Combining Interventions
10:40 Limits of Treatment Guidelines
12:18 The Future of Interventional Psychiatry
13:23 Emerging Technologies: Neurofeedback and Focused Ultrasound
17:15 Building a Comprehensive Interventional Program
18:13 Tools vs. Understanding Brain Circuits

This episode is intended for psychiatrists, mental health clinicians, and others interested in interventional approaches to complex psychiatric disorders.

This discussion is for educational purposes and does not substitute for individual clinical judgment or patient care.

Senior Producer: Jon Earle

The State of Precision Psychiatry Dec 19, 2025

To kick off Season 4, Charles Marmar, MD, explains how precision psychiatry is reshaping the way clinicians and researchers think about diagnosis, treatment selection, and the underlying biology of psychiatric disorders. This conversation is a overview of where the field stands today—including emerging molecular markers, biologically informed subtypes, and new translational approaches inspired by oncology and other precision-based specialties.

Dr. Marmar is Chair of Psychiatry at NYU Grossman School of Medicine, and Director of the Center for the Study of Alcohol Use Disorder and Traumatic Stress.

▶️ Watch Insights on Psychiatry on YouTube

In this episode, Dr. Marmar outlines current work on:

Molecular and genomic signatures that may distinguish patient subtypes
Clinical trials examining targeted treatments for alcohol use disorder
The development of proxy “brain biopsy” methods such as exosomal analyses and iPSC-derived organoids
How converging biological data could eventually support more individualized treatment planning

This discussion reflects ongoing efforts at NYU Langone Health to move psychiatry toward a more mechanism-based, biologically grounded model of care, while acknowledging the complexity and early stage of the work.

This episode is intended for psychiatrists, mental health clinicians, and others interested in the treatment of complex psychiatric disorders.

This discussion is for educational purposes and does not substitute for individual clinical judgment or patient care.

Senior Producer: Jon Earle

The Next Big Breakthrough May 21, 2025

What if mental health care worked more like cancer treatment—tailored to the individual, informed by biology, and driven by data? Charles Marmar, MD, Chair of Psychiatry at NYU Grossman School of Medicine, takes us through the latest advances in precision psychiatry. From brain imaging to digital phenotyping, Dr. Marmar outlines the tools shaping a future where treatment is fully customized. He also shares stories from the front lines: a patient whose depression was treated with the help of a brain biopsy, why PTSD and depression aren’t one-size-fits-all, and how quantum computing could radically accelerate psychiatric research.

🔍 Topics Covered

00:00 Introduction
02:24 Personalized Treatment Approaches
05:13 Challenges in Precision Psychiatry
11:12 The Role of Genomics and Brain Imaging
23:35 Digital Psychiatry and AI
25:57 Quantum Computing in Psychiatry
33:04 Future of Precision Psychiatry
37:22 Conclusion

📚 Related Resources

Charles Marmar, MD – NYU Faculty Profile
NYU Langone Psychiatry
Adriana Heguy, PhD – NYU Faculty Profile
Javad Shabani, PhD – NYU Faculty Profile

🙌 Support & Subscribe

If this episode challenged your thinking, like, share, and subscribe to help bring smart, science-forward conversations to a wider audience.

This discussion is for educational purposes and does not substitute for individual clinical judgment or patient care.

Senior Producer: Jon Earle

The Schizophrenia Puzzle is Solvable May 14, 2025

There’s a care model for schizophrenia that actually works—why isn’t it everywhere? On this episode, W. Gordon Frankle, MD, MBA, Vice Chair of Psychiatry at NYU Langone Health, shares how his team in Brooklyn is building a new model for treating serious mental illness—one rooted in long-term, relationship-driven, team-based care. From wraparound services to precision psychiatry, this conversation explores what happens when you bring humanity, structure, and innovation to a population too often left behind.

Also discussed:

The first novel schizophrenia drug in over 50 years (Cobenfy)
Why clozapine is underused—and how that may finally change
The potential of brain imaging and biomarkers in psychiatric treatment
What a real community mental health system looks like
Why trust, not just treatment, is essential for recovery

🔍 Topics Covered

00:00 Introduction
00:30 Dr. Frankle's Current Work
01:08 Advancements in Schizophrenia Research
02:29 Challenges and New Treatments in Schizophrenia
05:02 Precision Medicine in Psychiatry
05:59 PET Scans and Brain Energetics
09:46 Barriers to Effective Treatment
11:51 Clozapine and Treatment Access
13:38 Wraparound Services and Community Care
14:46 Early Screening and Public Health Interventions
18:32 Mandated Treatment and Patient Engagement
30:08 Homelessness and Mental Health
34:54 Future Directions in Schizophrenia Treatment
38:09 Conclusion

📚 Related Resources

W. Gordon Frankle, MD, MBA
Schizophrenia care at NYU Langone
NYU Langone Hospital—Brooklyn
3 Things to Know About Cobenfy (Yale Medicine)
🙌 Support & Engage

If you enjoyed this episode, please like, share, and subscribe to support real conversations about transforming mental health care.

This discussion is for educational purposes and does not substitute for individual clinical judgment or patient care.

Senior Producer: Jon Earle

How Psychedelics Rewire the Brain May 07, 2025

How could a single psychedelic treatment cause lasting change? Joshua Siegel, MD, PhD, is on a mission to find out. A leading expert on neuroimaging and neuropsychopharmacology at NYU Langone’s Center for Psychedelic Medicine, Dr. Siegel unpacks how psilocybin may spark neuroplasticity and reshape the depressed brain. He also gives us an inside look at the race to develop non-hallucinogenic psychedelic analogs.

Dr. Siegel is an assistant professor at NYU Grossman School of Medicine.

🔍 Topics Covered:

00:00 Introduction
00:15 Dr. Siegel's Current Work
01:01 Past Research and Human Psilocybin Imaging Study
02:39 Understanding Brain Changes and Biomarkers
06:13 Mechanisms of Action and Plasticity
12:51 Surprising Findings and Context Dependence
16:34 Challenges and Future Directions in Psychedelic Research
20:46 Advanced Imaging and Personalized Treatment Plans
24:15 Setbacks and Lessons in Psychedelic Medicine
28:40 Emerging Areas in Neuropsychopharmacology
31:46 Conclusion
📚 Related Resources:

Joshua Siegel, MD, PhD
NYU Langone Health’s Center for Psychedelic Medicine
The Multidisciplinary Association for Psychedelic Studies (MAPS)
“Psychedelic and Dissociative Drugs as Medicines” (NIH)
🙌 Support & Engage: Enjoyed this episode? Like, comment, and share to support science-based conversations about mental health.

🔔 Don’t forget to subscribe for more interviews with top psychiatric researchers.

This discussion is for educational purposes and does not substitute for individual clinical judgment or patient care.

Senior Producer: Jon Earle

Can AI Help Prevent PTSD? Apr 30, 2025

What if a simple conversation in the emergency room could reveal who’s most at risk for PTSD before symptoms even begin? Katharina Schultebraucks, PhD, shares her innovative work on using machine learning to forecast mental health outcomes and explains how AI could revolutionize how we detect, prevent, and treat psychiatric disorders. Dr. Schultebraucks is Co-Director of the Computational Psychiatry Program and Associate Professor in the Department of Psychiatry and Population Health at NYU Grossman School of Medicine.

🔍 Topics Covered
00:00 Introduction
00:23 Current Work and Research Focus
01:29 Objective Measures in Psychiatry
02:50 Predicting PTSD Risk
04:28 Early Preventive Interventions
05:47 Machine Learning in Mental Health
09:49 Challenges and Surprises in Research
22:46 Burnout in Emergency Department Providers
27:17 Precision Psychiatry and Future Directions
29:35 Conclusion

🔔 Subscribe for more conversations at the intersection of mental health and innovation.
📢 Like, comment, and share if this episode sparked your thinking.

This discussion is for educational purposes and does not substitute for individual clinical judgment or patient care.

Senior Producer: Jon Earle

ADHD at School: What Actually Helps Apr 23, 2025

How do you help a child with ADHD stay organized, on task, and confident in school? Richard Gallagher, PhD, a child and adolescent psychologist at NYU Langone Health, shares groundbreaking research on organizational skills training for children with ADHD—a behavioral treatment that’s changing lives and improving classroom performance. This episode dives into how executive functioning challenges manifest in real life, the strengths (and limits) of technology, and the power of parent training and therapeutic coaching to help children thrive.

Dr. Richard Gallagher is Associate Professor in the Department of Child and Adolescent Psychiatry at NYU Grossman School of Medicine, and Director of the Organization Skills Program.

🔍 Topics Covered

00:00 Introduction
00:19 Current Research on Organizational Skills
01:06 Executive Functioning and Practical Interventions
02:37 Impact of Interventions on ADHD
04:41 Expanding Research and Brain Connectivity
05:08 Medication and Organizational Skills
08:11 Technology in ADHD Assessment
15:39 Effective Parenting Styles for ADHD
23:10 Non-Pharmacological Treatments and Future Research
25:58 Conclusion and Final Thoughts

📚 Related Resources

👨‍⚕️More about Dr. Richard Gallagher
🔬 NYU Child Study Center
📘 “Organizational Skills Training for Children with ADHD” by Richard Gallagher, Howard B. Abikoff, and Elana G. Spira
📝 CHADD Parent Training Resources
📈 CDC ADHD Parent Guide

🙌 Support & Engage

If this episode was helpful, please like, share, and subscribe to support the series and spread awareness about evidence-based ADHD care.

This discussion is for educational purposes and does not substitute for individual clinical judgment or patient care.

Senior Producer: Jon Earle

The Hidden Adult ADHD Crisis Apr 16, 2025

ADHD isn’t just a childhood condition—many adults go undiagnosed for years. Lenard Adler, MD, Director of the Adult ADHD Program at NYU Langone Health, breaks down the nuances of ADHD in adults, the challenges of proper diagnosis, and the latest treatments available. Learn about his research, the screening tools his team has developed, and what’s on the horizon for adult ADHD care.

🔍 Topics Covered:

00:00 Introduction
00:44 Dr. Adler’s Current Research Focus
01:47 Importance of Proper Assessment
03:44 Challenges in Diagnosing Adult ADHD
06:15 Gender Differences in ADHD Diagnosis
07:51 Impact of ADHD on Lifespan
10:10 Comorbidities and Treatment Approaches
14:54 Medication and Treatment Strategies
21:15 Medication Shortages and Solutions
28:42 Recent Developments in ADHD Research
35:01 Screening and Diagnostic Tools
37:33 Conclusion

📚 Related Resources:

Lenard A. Adler, MD (official bio)
Adult ADHD Program at NYU Langone Health
Adult Self-Report Scale (ASRS) Screener
Life expectancy and years of life lost for adults with diagnosed ADHD in the UK: matched cohort study | The British Journal of Psychiatry
American Professional Society of ADHD and Related Disorders (APSARD)
CHADD: ADHD Resources and Support

🙌 Support & Engage: If you found this episode helpful, please like, comment, and share to spread awareness.

🔔 Don’t forget to subscribe to stay updated on new episodes.

This discussion is for educational purposes and does not substitute for individual clinical judgment or patient care.

Senior Producer: Jon Earle

How to Make Addiction Care Routine Apr 09, 2025

Despite affecting more Americans than diabetes, substance use is often left out of routine medical care. In this episode, NYU Langone Health’s Jennifer McNeely, MD—a clinician investigator, primary care and addiction medicine physician—explains why that must change. From the surprising history behind addiction’s exclusion from mainstream medicine to the innovative screening tools shaping the future of care, this conversation is a must-listen for anyone interested in addiction care and healthcare policy.

Jennifer McNeely, MD, is an Associate Professor of Medicine and Population Health at NYU Grossman School of Medicine and co-director of the Section on Tobacco, Alcohol, and Drug Use.

🔍 Topics Covered:

00:00 – Introduction
01:15 – Why addiction hasn’t been part of traditional medical care
05:00 – What medications can primary care providers actually prescribe?
07:00 – Why lifting legal barriers isn’t enough
08:00 – Making substance use screening part of routine care
11:50 – The power of self-report screening tools
13:30 – What primary care physicians can actually do after screening
16:10 – Real-world clinical impact of identifying substance use
18:00 – Overcoming stigma and “we don’t do that here” culture
22:17 – Can AI help with screening and care prioritization?

📚 Related Resources:

Jennifer McNeely, MD
Addiction Treatment at NYU Langone
NIDA’s Resources for Clinicians
Substance Use Screening Tools (NIDA)

🙌 Support & Engage: If you found this episode helpful, please like, comment, and share to spread awareness.

🔔 Don’t forget to subscribe to stay updated on new episodes.

This discussion is for educational purposes and does not substitute for individual clinical judgment or patient care.

Senior Producer: Jon Earle

The Key to Effective Addiction Care Apr 02, 2025

What makes addiction treatment truly effective? Behavioral scientist Charles Neighbors, MBA, PhD, shares groundbreaking research on the importance of therapeutic relationships, harm reduction, and human connection—love!—in treating substance use disorders. Dr. Neighbors is an Associate Professor in the Departments of Population Health, and Psychiatry at NYU Grossman School of Medicine.

💡 Topics Covered

00:00 Introduction to Dr. Charles Neighbors
01:37 The biggest challenges in addiction treatment
02:24 The Importance of Therapeutic Relationships
05:59 Defining “good treatment” and why love matters
08:05 The role of therapeutic alliance in patient outcomes
14:06 Barriers to change in addiction treatment systems (incl. stigma)
22:04 Harm reduction and safe injection sites: What does the science say?
30:36 Future directions in addiction policy and treatment

📚 Related Resources

Charles J. Neighbors, MBA, PhD (official bio)
Dr. Neighbors’ Lab - Health Evaluation & Analytics Lab (HEAL)
Addiction Treatment at NYU Langone
Understanding Harm Reduction: National Institute on Drug Abuse (NIDA)
"Motivational Interviewing" by William R. Miller and Stephen Rollnick
Community Reinforcement and Family Training (CRAFT)
SAMHSA’s National Helpline for Mental Health, Drug, Alcohol Issues
New York State Office of Addiction Services and Supports (OASAS)

🔔 Subscribe for more insights on mental health & addiction treatment!

👍 If you found this video helpful, please like, comment, and share to spread awareness!

This discussion is for educational purposes and does not substitute for individual clinical judgment or patient care.

Senior Producer: Jon Earle

Pediatric ADHD: Precision Strategies (with Samuele Cortese, MD, PhD) Apr 16, 2024

For the final episode of Season 2, we're joined by Dr. Samuele Cortese, Professor of Child and Adolescent Psychiatry at the University of Southampton (UK) and Adjunct Full Professor at NYU Langone. Together we explore the intersection of pediatric ADHD and precision psychiatry, including the disorder’s genetic underpinnings and evolving treatment options.
00:00 Introduction
00:54 Dr. Cortese's Research Journey
02:11 Global Perspectives and Challenges in ADHD Treatment
03:51 Advances in ADHD Diagnosis and Treatment
06:41 Role of Genetics in ADHD
09:33 Precision Treatment and Stratification
12:17 Treatment Adherence and Shared Decision-Making
23:55 Connection Between ADHD and Obesity
28:39 Non-Stimulant Alternatives and Future Directions in ADHD Treatment
32:16 Non-Pharmacological Treatments
37:28 Advice for Clinicians and Closing Thoughts

This discussion is for educational purposes and does not substitute for individual clinical judgment or patient care.

Senior Producer: Jon Earle

Pediatric ADHD: A Lifespan Approach (with Timothy Wilens, MD) Apr 09, 2024

Dr. Timothy Wilens is a Professor of Psychiatry at Harvard Medical School and Chief of the Division of Child and Adolescent Psychiatry at Massachusetts General Hospital. His research interest include the relationship between ADHD, bipolar disorder, and substance use disorders; ADHD pharmacotherapy; and stimulant medication misuse.
On this episode, Dr. Wilens discusses the importance of early diagnosis and intervention in ADHD, as well as its lifelong implications. He takes us through the evolution of ADHD treatment, from behavioral therapies to modern pharmacological interventions, including stimulant and non-stimulant medications, and the application of digital therapeutics. The conversation also touches on the stigma surrounding ADHD, the role of precision medicine, and the future of ADHD research.
00:00 Introduction
02:50 Evolution of ADHD Treatment
04:43 Stigma and Misconceptions
12:18 Importance of Early Intervention
15:02 ADHD Symptoms and Treatment Approaches
30:02 Addressing Concerns About Stimulant Medications
35:50 Navigating the Complexities of ADHD Medication
41:22 Future of ADHD Research and Treatment
43:20 Conclusion

This discussion is for educational purposes and does not substitute for individual clinical judgment or patient care.

Senior Producer: Jon Earle

Schizophrenia (with Ira Glick, MD) Apr 02, 2024

Dr. Ira Glick is Professor Emeritus of Psychiatry and Behavioral Sciences at Stanford University Medical Center, where he has served as director of the Schizophrenia Research Clinic. On this episode, he discusses his research journey, which began in the 1960s and followed a shift from psychoanalysis to biological psychiatry. He addresses the broken social safety net for schizophrenia patients, including the controversial topic of treating some patients against their will, as well as the challenges of medication adherence, and the stigma surrounding severe mental illness.
00:00 Introduction
00:49 Evolution of Schizophrenia Treatment
04:34 Science Behind Schizophrenia Medications
07:39 Addressing the Public Health Challenges of Schizophrenia
11:15 Stigma and Misunderstanding of Severe Mental Illness
21:44 Innovative Treatment Approaches and the Future of Schizophrenia Care
31:36 Importance of Public Health Interventions and Political Will
35:45 Closing Remarks and Future Directions

This discussion is for educational purposes and does not substitute for individual clinical judgment or patient care.

Senior Producer: Jon Earle

Mental Health Equity (with Christin Drake, MD) Mar 26, 2024

Dr. Christin Drake is Clinical Associate Professor and Vice Chair of Diversity and Equity in the Department of Psychiatry at NYU Grossman School of Medicine. On this episode, Dr. Drake discusses ongoing efforts to improve mental health equity, including by improving psychiatric services for underserved groups, gathering better data, and boosting diversity among health care providers. She also discusses the importance of integrating mental health care into perinatal services and challenges the conventional wisdom about stigma toward mental health care in the Black community.
00:00 Introduction
00:55 Dr. Drake's Vision for Equity in Mental Health Care
03:46 Addressing Racial Inequities in Psychiatry: A Critical Conversation
04:45 The Importance of Representation and Mentorship in Psychiatry
10:32 Building Foundations for Health Equity: Data and Systemic Change
22:16 Integrating Psychiatric Care into Perinatal Health
33:31 Rethinking Mental Health Stigma in the Black Community
38:08 Future Projects and Closing Thoughts

This discussion is for educational purposes and does not substitute for individual clinical judgment or patient care.

Senior Producer: Jon Earle

Ketamine (with John Krystal, MD) Mar 19, 2024

Dr. John Krystal is Chair of Psychiatry at the Yale School of Medicine. He is best known for leading the discovery of the rapid antidepressant effects of ketamine, which paved the way for the first major new antidepressant drug in decades. Here, Dr. Krystal talks about what we’ve learned in the five years since esketamine nasal spray was approved by the FDA, including efforts to predict treatment response, dosage and frequency, safety, and long-term impact. He also discusses advances in our understanding of alcohol use disorder and weighs in on the search for psychiatric biomarkers.
00:00 Introduction
01:01 Dr. Krystal's Research Journey
03:32 What We’ve Learned Since Esketamine’s FDA Approval
05:59 Avoiding Misuse
08:11 Optimizing Dosage
16:25 Predicting Treatment Outcomes
24:17 Ketamine vs. Psychedelics
25:48 Advances in the Treatment of Alcohol Use Disorder
32:33 Precision Psychiatry and Personalized Treatment Approaches
39:49 Psychiatric Biomarkers
41:03 The Future of Psychiatric Research and Treatment

This discussion is for educational purposes and does not substitute for individual clinical judgment or patient care.

Senior Producer: Jon Earle

Struggling Kids & Teens (with Robert Findling, MD) Mar 12, 2024

Dr. Robert Findling is Chair of the Department of Psychiatry at the Virginia Commonwealth University School of Medicine. Here he discusses recent advances in pediatric mental health, including his own research on aggression and schizophrenia in young people. Dr. Findling also shares his thoughts on the crisis of teen suicide, the lingering impact of COVID-19 on children’s mental health, and the need for early and collaborative interventions.
00:00 Introduction
00:46 Clinical and Research Journey
02:56 Aggression with impulsivity and reactivity (AIR)
06:48 Precision Pediatric Psychiatry
15:34 Schizophrenia
20:31 What Kids Need to Thrive
23:10 Teen Suicide
25:09 Role of Schools and Primary Care
30:58 Loneliness Epidemic Among Children
32:32 Improving Access to Pediatric Mental Health Care
40:00 Bipolar Disorder
43:24 Future Research and Hope for Young Patients
45:11 Conclusion: Importance of Early Intervention

This discussion is for educational purposes and does not substitute for individual clinical judgment or patient care.

Senior Producer: Jon Earle

Frontiers of Psychopharmacology (with Charles Nemeroff, MD, PhD) Mar 05, 2024

Dr. Charles Nemeroff is Chair of the Department of Psychiatry and Behavioral Sciences at the University of Texas-Austin's Dell Medical School. He is also co-director of the Center for Psychedelic Research and Therapy, and director of the Institute for Early Life Adversity Research. His research is focused on the pathophysiology of mood and anxiety disorders with a focus on the role of child abuse and neglect as a major risk factor.
00:00 Introduction
00:52 Dr. Nemeroff's Research Journey
01:55 Childhood Maltreatment as Risk Factor
04:53 Advances and Challenges in Precision Psychiatry
07:33 Psychedelic Medicine (incl. blinding issues and potential adverse events)
20:50 How Psychedelics Disrupt the "Circle of Hell"
30:00 Psilocybin as Potential Treatment for Anorexia Nervosa
38:32 Screening for Childhood Maltreatment
41:30 Transcranial Magnetic Stimulation (TMS)
44:14 Focused Ultrasound
46:32 Prescribing MAOIs
49:34 Conclusion

This discussion is for educational purposes and does not substitute for individual clinical judgment or patient care.

Senior Producer: Jon Earle

Empathy Training (with Helen Riess, MD) Feb 27, 2024

Dr. Helen Riess is Associate Clinical Professor of Psychiatry at Harvard Medical School and Director of Empathy Research and Training in the Psychotherapy Research Group at Massachusetts General Hospital. She is also Founder and Chief Executive Officer at Empathetics, a company that provides science-based empathy and interpersonal skills training for healthcare professionals. Her research focuses on improving empathy and relational skills in physicians.
00:00 Introduction
01:14 Defining Empathy
03:38 Empathy and Burnout
05:00 Care for the Caregiver
07:52 Exquisite Empathy and Burnout
09:18 Building Empathy and Avoiding Overburden
10:45 Developing Boundaries in Clinical Practice
11:45 Training and Teaching Empathy
13:42 Model for Recognizing Emotion in Others
15:11 Becoming Emotion Detectives
19:31 Leadership's Role in Creating Supportive Workplaces
23:22 Benefits of Empathy Training
29:07 Technology and Empathy Training
34:18 Research on MDMA-Assisted Psychotherapy
37:43 Building Empathy and Compassion
40:07 Taking Small Steps Towards Empathy
42:32 Resources for Building Empathy
43:28 Future of Empathy Training
The Empathy Effect (Dr. Riess's book)
The Power of Empathy (TEDx Talk)

This discussion is for educational purposes and does not substitute for individual clinical judgment or patient care.

Senior Producer: Jon Earle

Obsessive-Compulsive Disorder (with Christopher Pittenger, MD, PhD) Feb 20, 2024

Dr. Christopher Pittenger is a Professor of Psychiatry at the Yale School of Medicine and Director of the Yale OCD Research Clinic. In this episode, he discusses the neurobiology, symptomology, and treatment of Obsessive-Compulsive Disorder (OCD), including potential new treatments such as psychedelics, neurofeedback, glutamate modulators, and transcranial magnetic stimulation (TMS).
00:00 Introduction
00:41 Why is OCD Underdiagnosed?
02:19 Impact of OCD on Individuals
03:40 Taboo Nature of OCD Thoughts
06:10 Biomarkers
08:06 Neurobiology
14:20 Serotonin
16:48 Heterogeneity of OCD
24:00 Glutamate Modulators
29:33 Ketamine
33:13 Psilocybin
38:23 Neurofeedback
44:01 Transcranial Magnetic Stimulation (TMS)
47:22 Relationship Between Depression and OCD
50:24 Future of OCD Treatment

This discussion is for educational purposes and does not substitute for individual clinical judgment or patient care.

Senior Producer: Jon Earle

Meditation (with Richard Davidson, PhD) Feb 13, 2024

Dr. Richard Davidson is the William James and Vilas Professor of Psychology and Psychiatry at the University of Wisconsin–Madison and Founder & Director of the Center for Healthy Minds. In this episode, he discusses the current state of research on mindfulness and meditation as mental health interventions.
00:00 Introduction
02:15 Focus areas in current research
04:37 Well-being as a universal intervention
06:21 Beyond mindfulness: other forms of meditation
07:24 Four pillars of well-being: awareness, connection, insight, and purpose
13:04 Healthy Minds Program and the impact of short daily meditation practices
17:05 Comparison of Mindfulness-Based Stress Reduction (MBSR) and the Healthy Minds Program, focusing on accessibility and time commitment
20:55 The potential for structural changes in the brain with meditation
26:24 Integrating mindfulness and meditation into clinical practice
28:06 Micro-supports for everyday well-being
33:27 Mindfulness and social connection
35:06 Future research directions, including the concept of a flourishing city

This discussion is for educational purposes and does not substitute for individual clinical judgment or patient care.

Senior Producer: Jon Earle

Precision Psychiatry (with Ronald Kessler, PhD) Feb 06, 2024

Dr. Ronald Kessler is the McNeil Family Professor of Health Care Policy at Harvard Medical School. His groundbreaking work on the social determinants of mental health, studied from an epidemiological perspective, has made him the most widely cited psychiatric researcher in the world. In this wide-ranging conversation, he talks about precision psychiatry's enormous potential and incremental development, delving into his own efforts to better identify at-risk patients and predict treatment efficacy. Dr. Kessler stresses the need for better data and bigger studies, and envisions a future of AI-supported clinicians.
00:00 Introduction
00:53 Dr. Kessler's Journey to Precision Psychiatry
02:45 The Importance of Data
04:14 Risk Factors and Treatment Optimization
10:42 Successes and Challenges
13:23 The Importance of Baseline Information
23:46 Machine Learning in Veterans Health
24:27 Determining Suicide Risk
25:35 Interventions and Cost-Effectiveness
26:16 Esketamine Trials and Response Prediction
27:07 Risk Models and Comparative Risk Models
27:15 Insomnia Treatment in Military Personnel
29:36 Cost-Benefit Analyses
35:45 AI in Medicine and Patient Response
42:21 Future of Precision Psychiatry
45:51 Closing Remarks

This discussion is for educational purposes and does not substitute for individual clinical judgment or patient care.

Senior Producer: Jon Earle

Addiction (with Petros Levounis, MD, MA) Jan 30, 2024

Dr. Petros Levounis is President of the American Psychiatric Association and a leader in addiction research. He joins host Thea Gallagher, PsyD, to talk about the latest in addiction medicine, the state of the opioid crisis, the growing problem of technology addiction, and the promise and risks of psychedelic medicine. He also shares his hopes for the future of psychiatry, including better integration of diagnoses, treatments, and outcomes for people with mental health disorders.
00:00 Introduction to NYU Langone Insights on Psychiatry
00:16 Dr. Levounis's role and priorities as APA president
00:46 The State of Addiction Medicine
02:12 Neurobiology of Addiction
03:37 Interplay Between Mental Health and Addiction
06:03 Potential and Challenges of Psychedelic Medicine
08:37 Cannabis and Tech Addictions
10:11 Addressing the Opioid Crisis: Strategies and Solutions
15:28 Addressing Technological Addictions
28:55 The Future of Psychiatry: Goals and Aspirations
35:47 Conclusion and Final Thoughts

This discussion is for educational purposes and does not substitute for individual clinical judgment or patient care.

Senior Producer: Jon Earle

Season 2 Announcement Oct 30, 2023

Starting this fall, we're releasing 12 more conversations with the best minds in psychiatry. Subscribe wherever you're listening, so you won't miss an episode.

This discussion is for educational purposes and does not substitute for individual clinical judgment or patient care.

Senior Producer: Jon Earle

Biomarkers for Depression (with Carla Nasca, PhD) Jul 18, 2023

Dr. Carla Nasca is an Assistant Professor in the Department of Psychiatry and the Department of Neuroscience and Physiology at NYU Langone, where she studies epigenetic mechanisms of neuroplasticity to stress. Dr. Nasca's work led to the discovery of acetyl-L-carnitine (LAC), a metabolite found in the mitochondria, as a promising biological marker of depression.
Topics:

acetyl-L-carnitine (LAC) and major depressive disorder
How stress changes the brain on a structural/molecular level
Risk factors for stress-induced disorders
Machine learning

More information: https://www.cdr.rfmh.org/research/nasca-lab/

This discussion is for educational purposes and does not substitute for individual clinical judgment or patient care.

Senior Producer: Jon Earle

Dopamine (with Tanya Sippy, MD, PhD) Jul 06, 2023

Dr. Tanya Sippy is an Assistant Professor in the Department of Psychiatry and the Department of Neuroscience and Physiology at NYU Langone. She’s also Principal Investigator at the Sippy Lab and Associate Director of the Psychedelic Medicine Research Training Program. Her research explores the neural mechanisms that underlie how sensory stimuli become associated with goal-directed behavior.
Topics:

How learning changes sensory representation (with implications for understanding addiction, etc.)
Recent research on the functions of dopamine and serotonin
Hype vs reality of psychedelics
Regulation of ketamine clinics

More information: https://www.sippylab.com/

This discussion is for educational purposes and does not substitute for individual clinical judgment or patient care.

Senior Producer: Jon Earle

Bipolar Disorder (with Andrew Nierenberg, MD) Jun 20, 2023

Dr. Andrew Nierenberg is a Professor of Psychiatry at Harvard Medical School and Director of the MGH Dauten Family Center for Bipolar Treatment Innovation. He completed his residency in psychiatry at New York University/Bellevue Hospital.
Topics:

Lithium vs antipsychotics
SMART BD (Sequential Multiple Assignment of Randomized Treatment)
Bipolar Learning Health Network
Medication concordance

More information:
https://brain.harvard.edu/?people=andrew-nierenberg

This discussion is for educational purposes and does not substitute for individual clinical judgment or patient care.

Senior Producer: Jon Earle

Depressive Disorders (with Alan Schatzberg, MD) Jun 08, 2023

Dr. Alan Schatzberg is a Professor of Psychiatry and Behavioral Sciences at Stanford Medicine, and Director of the Stanford Mood Disorders Center. His research examines the biology and psychopharmacology of depressive disorders. An NYU School of Medicine alumnus, Dr. Schatzberg was President of the American Psychiatric Association from 2009-2010.
Topics:

Ketamine and Esketamine (incl. mechanisms of action)
Ketamine and obsessive-compulsive disorder
Opioids
Psychedelic medicine

For more information:
https://med.stanford.edu/profiles/alan-schatzberg

This discussion is for educational purposes and does not substitute for individual clinical judgment or patient care.

Senior Producer: Jon Earle

Psychedelic Medicine (with Michael Bogenschutz, MD) May 23, 2023

Dr. Michael Bogenschutz is a Professor of Psychiatry at the NYU Grossman School of Medicine, and Director of the NYU Langone Center for Psychedelic Medicine.
Topics:

Psilocybin-assisted psychotherapy for alcohol use disorder
MDMA-assisted psychotherapy for PTSD
Psychedelic medicine for the "worried well"
The role of the mystical experience
Comparing different psychedelic medicines
Mechanisms of action
Treatment protocols
Safety and risk-mitigation
Topics for further investigation

Cited:

Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder (August 2022)

For more information:
https://centerforpsychedelicmedicine.org/

This discussion is for educational purposes and does not substitute for individual clinical judgment or patient care.

Senior Producer: Jon Earle

Sleep and Alzheimer's Disease (with Omonigho M. Bubu, MD, MPH, PhD) May 09, 2023

Dr. Omonigho M. Bubu is an Assistant Professor of Psychiatry and Population Health at the NYU Grossman School of Medicine, where he studies the connection between sleep and neurodegenerative diseases, as well as social determinants of health as they relate to cognitive health. In this interview, he discusses the importance of sleep, especially for people at higher risk of developing Alzheimer’s disease.

Topics:

Alzheimer’s disease (AD)
Associations between sleep and increased AD risk
Sleep patterns in minoritized communities
Obstructive sleep apnea
Dementia and cognitive decline
Social determinants of health

Cited:

Visit our website for more information:
https://physicianfocus.nyulangone.org/nyu-langone-insights-on-psychiatry-podcast/

This discussion is for educational purposes and does not substitute for individual clinical judgment or patient care.

Senior Producer: Jon Earle

Mindfulness-Based Stress Reduction (with Naomi Simon, MD) Apr 21, 2023

Naomi Simon, MD, talks about her research into mindfulness-based stress reduction (MBSR) and yoga as treatments for anxiety disorders. Dr. Simon is a Professor in the Department of Psychiatry at the NYU Grossman School of Medicine, and Director of the Anxiety, Stress, and Prolonged Grief Program.

Topics:

Generalized Anxiety Disorder (GAD)
Mindfulness-Based Stress Reduction (MBSR)
Kundalini yoga
Selective serotonin reuptake inhibitors (SSRIs)
Access to MBSR & Yoga (including smartphone apps)
Cognitive behavioral therapy (CBT)
Exercise
Mechanism(s) of action

Cited: Mindfulness-Based Stress Reduction vs Escitalopram for the Treatment of Adults With Anxiety Disorders (Nov. 2022)

This discussion is for educational purposes and does not substitute for individual clinical judgment or patient care.

Senior Producer: Jon Earle

Fear Conditioning (with Mohammed Milad, PhD) Apr 10, 2023

Mohammed Milad, PhD, discusses recent research into fear conditioning, regulation, and extinction. Dr. Milad is a Professor in the Department of Psychiatry at the NYU Grossman School of Medicine and Director of the Behavioral Neuroscience Program.
Topics covered:

Transcranial magnetic stimulation (TMS)
Estrogen and PTSD
Post-traumatic stress disorder (PTSD)
Meditation
Deep brain stimulation

This discussion is for educational purposes and does not substitute for individual clinical judgment or patient care.

Senior Producer: Jon Earle

Health Equity (with Ayana Jordan, MD, PhD) Mar 17, 2023

Ayana Jordan, MD, PhD, is the Barbara Wilson Associate Professor of Psychiatry at the NYU Grossman School of Medicine, an Associate Professor in the Department of Population Health, and the Pillar Lead for the Institute for Excellence in Health Equity.
Topics covered:

Lack of improvement in health equity nationwide
Advice for clinicians on providing equitable care
Structural competence vs. cultural competence
Thoughts on integrating alternative therapies (ex. acupuncture, spirituality)
Using data to improve health equity

This discussion is for educational purposes and does not substitute for individual clinical judgment or patient care.

Senior Producer: Jon Earle

Adult ADHD (with Lenard Adler, MD) Feb 23, 2023

Lenard A. Adler, MD, is a Professor of Psychiatry and Child and Adolescent Psychiatry at the NYU Grossman School of Medicine and Director of the Adult ADHD Program at NYU Langone Health.

Topics covered:

Symptomology (incl. sluggish cognitive tempo)
Screening and diagnostic tools
Pharmacological treatments (and recent developments)
Cognitive behavioral therapy (CBT)
Medication shortage
Approaches to treatment-refractory patients

This discussion is for educational purposes and does not substitute for individual clinical judgment or patient care.

Senior Producer: Jon Earle

Treatment-Resistant Depression (with Dan Iosifescu, MD) Feb 21, 2023

Dan Iosifescu, MD, is an Associate Professor of Psychiatry at the NYU Grossman School of Medicine and director of clinical research at the Nathan Kline Institute for Psychiatric Research. His research has led to the validation of novel treatments for patients with severe mood and anxiety disorders, including pharmacological treatments such as ketamine and other glutamatergic drugs, and devices such as novel forms of magnetic stimulation.
Topics covered:

Ketamine and Esketamine
Why certain people respond better to certain medications
SSRI mechanism of action
Transcranial magnetic stimulation

This discussion is for educational purposes and does not substitute for individual clinical judgment or patient care.

Senior Producer: Jon Earle

PTSD & Precision Medicine (with Charles Marmar, MD) Feb 16, 2023

Charles R. Marmar, MD, is the Peter H. Schub Professor of Psychiatry and Chair of the Department of Psychiatry at NYU Langone Health. He also serves as Director of the Center for Precision Medicine in Alcohol Use Disorders and Post-Traumatic Stress Disorder (PTSD) and as Executive Director of the Steven A. Cohen Military Family Center.
Topics covered:

The shortcomings of existing "gold-standard" treatments for PTSD
Creating subtypes of PTSD
Study of gabapentin enacarbil and heavy drinkers
Study of gender differences in efficacy of SSRIs and other antidepressants
The need for objectivity in psychiatric diagnosis and treatment

Internationally renowned for his expertise in PTSD for over 25 years, Dr. Marmar's focus ranges from combat-related conditions in military veterans to PTSD in refugees and earthquake victims. He has served on multiple committees and scientific advisory groups at the national level for both the Department of Veterans Affairs and the National Institute of Mental Health (NIMH) and as counsel to the VA Medical Centers, fire departments, disaster response teams and police departments, including the NYPD.

This discussion is for educational purposes and does not substitute for individual clinical judgment or patient care.

Senior Producer: Jon Earle

Our TOPPODCAST Picks

Follow Us

Stay Connected

NYU Langone Insights on Psychiatry

Related Podcasts

Links

Stay Connected